Tirzepatide dosing charts on TikTok: what labs say vs. reality

What did @tirzepatida.flori actually say?

Honestly, this is an unusual case. The transcript captured from this video contains no intelligible health claims at all. What was recorded reads as: "Oh baby, you must be sure to wear Oh, so can you be sure to wear" — which appears to be audio recognition picking up background music rather than the creator's actual spoken content.

The caption, however, does make a few soft claims worth examining. The creator frames the content as "tips guided by laboratories" related to tirzepatide, and uses the disclaimer that "nothing here replaces your doctor's guidance." The hashtags point squarely at tirzepatide for weight loss. So we have a video positioned as dosing or protocol guidance for a GLP-1 receptor agonist, with a visual element (described as a "table") that we cannot verify from the transcript alone.

This matters because 97,300 people watched it. Even a passive visual slide with tirzepatide dosing information carries real risk if it is inaccurate or decontextualized.

Does the science back this up?

We cannot evaluate claims we cannot read. That is the honest answer here. What we can evaluate is the general claim that "laboratory-guided tips" on tirzepatide are appropriate to share via a TikTok slide without clinical supervision. The evidence says: not really.

Tirzepatide (brand names Mounjaro for type 2 diabetes, Zepbound for obesity) is a dual GIP and GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed mean weight reduction of up to 22.5% at the highest dose over 72 weeks, but that study was conducted under strict medical supervision with regular titration monitoring. The SURPASS trial series similarly showed strong glycemic outcomes in type 2 diabetes, again under protocol-driven care.

The point is that manufacturer prescribing information, which is likely what this creator means by "laboratory tips," is written for prescribers, not for patients self-navigating a dosing schedule on social media. Eli Lilly's own titration guidance assumes a clinician is monitoring tolerability, labs, and contraindications.

What did they get wrong (or right)?

The disclaimer is right. "Nothing here replaces your doctor's guidance" is the correct framing, and credit where it is due: the creator included it. The acknowledgment that "each treatment is individual" is also accurate and reflects real clinical practice. Tirzepatide dosing is highly individualized based on tolerability, baseline weight, renal function, and comorbidities.

What is potentially problematic is the framing of manufacturer information as "tips" you can apply yourself. Prescribing information is not a self-help guide. When creators present titration tables to nearly 100,000 viewers as actionable guidance, even with a disclaimer, research on health misinformation suggests disclaimers are frequently ignored. A 2022 study by Vraga and Bode in the journal Health Communication found that corrections and disclaimers on social media have limited impact on belief change, particularly when the primary content is visually compelling.

Without seeing the actual table shown in the video, we cannot say it was wrong. But we also cannot say it was right. That ambiguity is itself a problem at this scale.

What should you actually know?

Tirzepatide dosing follows a structured titration. The standard starting dose is 2.5 mg weekly for four weeks, with increases in 2.5 mg increments typically every four weeks as tolerated, up to a maximum of 15 mg weekly. This schedule exists because side effects, primarily nausea, vomiting, and gastroparesis-like symptoms, are strongly dose-dependent.

Skipping titration steps or accelerating dose increases based on a social media table rather than clinician guidance is where real harm can occur. Compounded tirzepatide, which many patients in Brazil and elsewhere access due to cost, introduces additional variables around concentration and sterility that make self-guided dosing even riskier. Compounded formulations are not equivalent to FDA-approved or ANVISA-approved brand-name products, and should never be treated as interchangeable.

If you are on tirzepatide or considering it, your prescriber should be managing your titration. A TikTok table, even one sourced from manufacturer documentation, is not a substitute for that relationship.